Bristol-Myers Squibb Submits NDAs for 2 Hepatitis C Medications
April 10th 2014Bristol-Myers Squibb submitted NDAs for daclatasvir and asunaprevir. Although asunaprevir is limited to treatment of genotype-1 HCV, a combination of daclatasvir with sofosbuvir may be useful in a range of HCV genotypes.
Read More